Reported results
- Collaboration revenue was $34.1 million for the three months ended September 30, 2026, compared to $11.7 million for the three months ended September 30, 2025.
- Research and development (R&D) expenses were $33.4 million for the three months ended September 30, 2026, compared to $58.4 million for the three months ended September 30, 2025.
- General and administrative (G&A) expenses were $14.1 million for the three months ended September 30, 2026, compared to $18.9 million for the three months ended September 30, 2025.
- Net loss was $10.5 million, or $(0.15) basic and diluted net loss per share, for the three months ended September 30, 2026.
- Cash and cash equivalents were $469.9 million as of September 30, 2026, compared to $628.1 million as of December 31, 2025.
Guidance
- Initiation of the first company-sponsored radioligand clinical trial for BT1702 is expected in the second half of 2027.
- The company expects to report Duravelo-2 survival data from the randomized Phase 2 trial in the second half of 2027.
- The company has an expected cash runway into 2030.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
